Columbia Care Inc. (OTCMKTS:CCHWF) has earned an average recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.25.
Several research firms recently issued reports on CCHWF. Jefferies Financial Group began coverage on shares of Columbia Care in a research report on Wednesday, July 7th. They set a “buy” rating and a $19.00 price objective for the company. Cantor Fitzgerald upgraded shares of Columbia Care from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $5.30 to $5.50 in a research note on Friday, August 27th. Finally, Canaccord Genuity raised shares of Columbia Care to a “buy” rating in a research note on Thursday, August 5th.
CCHWF traded down $0.09 during midday trading on Wednesday, hitting $3.94. 405,485 shares of the company traded hands, compared to its average volume of 589,587. Columbia Care has a 52-week low of $3.14 and a 52-week high of $7.89. The business has a 50 day simple moving average of $4.39 and a two-hundred day simple moving average of $5.33.
Columbia Care, Inc engages in the cultivation, manufacture and provision of medical cannabis products and services. It distributes its products under the EleCeed, TheraCeed, and ClaraCeed brands. The company was founded by Nicholas Vita and Michael Abbott in 2012 and is headquartered in New York, NY.
Featured Article: Return on Equity (ROE)
Receive News & Ratings for Columbia Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Columbia Care and related companies with MarketBeat.com's FREE daily email newsletter.